Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma (PROTECT)
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Sponsor: Centre Hospitalier Universitaire de Nice
This PHASE3 trial investigates Ocular Melanoma and is currently completed. Centre Hospitalier Universitaire de Nice leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Nice
For direct contact, visit the study record on ClinicalTrials.gov .